A US federal judge has ruled that a lawsuit can move forward against the US Patent and Trademark Office (PTO) and Myriad Genetics, which licensed patents covering the BRCA1 and BRCA2 genes known to help detect an increased risk of breast cancer and ovarian cancer1
...
Please login to read the full article.
